David Canner
Fortuna: - $ al 30/06/2026
Fortuna: - $ al 30/06/2026
David Canner is currently an Independent Director at Inhibikase Therapeutics, Inc. since 2024.
Dr. Canner is also a Partner at Soleus Capital LLC since 2018.
Dr. Canner holds a doctorate from the Massachusetts Institute of Technology and an undergraduate degree from Princeton University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 26/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director/Miembro de la Junta | 21/10/2024 |
Soleus Capital LLC | Corporate Officer/Principal | 01/01/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small-molecule kinase inhibitor therapeutics for neurological diseases | Health Technology |
Soleus Capital LLC |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.